US2012093816A1PendingUtilityA1

Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus

58
Assignee: OLMARKER KJELLPriority: Sep 25, 1998Filed: Nov 14, 2011Published: Apr 19, 2012
Est. expirySep 25, 2018(expired)· nominal 20-yr term from priority
Inventors:Kjell OlmarkerBjorn Rydevik
A61K 31/501A61K 38/40A61K 31/4045C07K 2317/24A61K 2039/505A61K 31/496A61K 38/1793A61K 31/00A61K 2039/507C07K 2317/76A61K 31/65C07K 16/245A61K 31/5383A61K 31/444A61K 31/454C07K 16/2875C07K 16/241A61K 38/20A61P 25/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A method of treating or alleviating one or more symptoms of a spinal disorder mediated by nucleus pulposus in a mammal, which spinal disorder is not arthritis or a related inflammatory disorder, said method comprising administering a therapeutically effective amount of a TNF-α inhibitor to the mammal, wherein the TNF-α inhibitor is an antibody that blocks TNF-α activity. 
     
     
         18 . The method of  claim 17 , wherein the spinal disorder involves one or more symptoms of pain. 
     
     
         19 . The method of  claim 17 , wherein the spinal disorder is a disc disorder or sciatica. 
     
     
         20 . The method of  claim 17 , wherein the spinal disorder is a disorder of a vertebral bone. 
     
     
         21 . The method of  claim 17 , wherein the spinal disorder involves structural or functional damage to nerves. 
     
     
         22 . The method of  claim 21 , wherein the spinal disorder involves structural or functional damage to nerves which are situated close to a disc and/or to nucleus pulposus. 
     
     
         23 . The method of  claim 17 , wherein the spinal disorder involves mechanical deformation of a nerve. 
     
     
         24 . The method of  claim 17 , wherein the spinal disorder involves reduced nerve root conduction. 
     
     
         25 . The method of  claim 17 , wherein said spinal disorder is caused by a disc herniation. 
     
     
         26 . The method of  claim 17 , wherein said spinal disorder is sciatica. 
     
     
         27 . The method of  claim 17 , wherein the TNF-α inhibitor is administered locally. 
     
     
         28 . The method of  claim 17 , wherein the TNF-α inhibitor is administered parenterally. 
     
     
         29 . The method of  claim 28 , wherein the TNF-α inhibitor is administered via intramuscular (i.m.), or intravenous (I.V.) injection. 
     
     
         30 . The method of  claim 28 , wherein the TNF-α inhibitor is administered epidurally. 
     
     
         31 . The method of  claim 17 , wherein the TNF-α inhibitor is administered orally. 
     
     
         32 . The method of  claim 17 , wherein the TNF-α inhibitor is administered systemically. 
     
     
         33 . The method of  claim 17 , wherein the antibody that blocks TNF-α activity is a complete or intact antibody. 
     
     
         34 . The method of  claim 17 , wherein the antibody that blocks TNF-α activity is selective for TNF-α. 
     
     
         35 . The method of  claim 17 , wherein the antibody that blocks TNF-α activity is selected from the group consisting of murine monoclonal antibodies, chimeric antibodies, humanized antibodies, and human monoclonal antibodies. 
     
     
         36 . The method of  claim 17 , wherein the antibody that blocks TNF-α activity is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870. 
     
     
         37 . The method of  claim 17 , wherein the antibody that blocks TNF-α activity comprises an immunogenic fragment of an antibody which binds to an epitope of TNF-α. 
     
     
         38 . The method of  claim 37 , wherein the immunogenic fragment is selected from the group consisting of Fab fragments, scFv, and F(ab)2 fragments. 
     
     
         39 . The method of  claim 17 , wherein the antibody that blocks TNF-α activity is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. 
     
     
         40 . The method of  claim 39 , wherein the pharmaceutical composition is a liquid solution, an emulsion, or a suspension. 
     
     
         41 . The method of  claim 39 , wherein the pharmaceutical composition comprises a carrier selected from gum Arabic, xanthan gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, polyvinylalcohol, ethyl oleate, a glycol, a polyethylene sorbitan fatty acid ester surfactant, and lecithin. 
     
     
         42 . The method of  claim 39 , wherein the pharmaceutical composition comprises lidocaine hydrochloride. 
     
     
         43 . The method of  claim 17 , wherein the mammal is a human. 
     
     
         44 . A method for treatment of a disorder selected from the group consisting of nerve root injury, sciatica, low back pain, whiplash associated disorder, nucleus pulposus-induced nerve injury, spinal cord compression, cervical rhizopathy, and a nerve disorder caused by a disk herniation in a mammal comprising administering to the mammal a therapeutically effective dosage of a TNF-α inhibitor to the mammal, wherein the TNF-α inhibitor is an antibody that blocks TNF-α activity. 
     
     
         45 . The method of  claim 44 , wherein the spinal disorder involves one or more symptoms of pain. 
     
     
         46 . The method of  claim 44 , wherein the spinal disorder is a disc disorder or sciatica. 
     
     
         47 . The method of  claim 44 , wherein the spinal disorder is a disorder of a vertebral bone. 
     
     
         48 . The method of  claim 44 , wherein the spinal disorder involves structural or functional damage to nerves. 
     
     
         49 . The method of  claim 48 , wherein the spinal disorder involves structural or functional damage to nerves which are situated close to a disc and/or to nucleus pulposus. 
     
     
         50 . The method of  claim 44 , wherein the spinal disorder involves mechanical deformation of a nerve. 
     
     
         51 . The method of  claim 44 , wherein the spinal disorder involves reduced nerve root conduction. 
     
     
         52 . The method of  claim 44 , wherein said spinal disorder is caused by a disc herniation. 
     
     
         53 . The method of  claim 44 , wherein said spinal disorder is sciatica. 
     
     
         54 . The method of  claim 44 , wherein the TNF-α inhibitor is administered locally. 
     
     
         55 . The method of  claim 44 , wherein the TNF-α inhibitor is administered parenterally. 
     
     
         56 . The method of  claim 55 , wherein the TNF-α inhibitor is administered via intramuscular (i.m.), or intravenous (I.V.) injection. 
     
     
         57 . The method of  claim 55 , wherein the TNF-α inhibitor is administered epidurally. 
     
     
         58 . The method of  claim 44 , wherein the TNF-α inhibitor is administered orally. 
     
     
         59 . The method of  claim 44  wherein the TNF-α inhibitor is administered systemically. 
     
     
         60 . The method of  claim 44 , wherein the antibody that blocks TNF-α activity is a complete or intact antibody. 
     
     
         61 . The method of  claim 44 , wherein the antibody that blocks TNF-α activity is selective for TNF-α. 
     
     
         62 . The method of  claim 44 , wherein the antibody that blocks TNF-α activity is selected from the group consisting of murine monoclonal antibodies, chimeric antibodies, humanized antibodies, and human monoclonal antibodies. 
     
     
         63 . The method of  claim 44 , wherein the antibody that blocks TNF-α activity is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870. 
     
     
         64 . The method of  claim 44 , wherein the antibody that blocks TNF-α activity comprises an immunogenic fragment of an antibody which binds to an epitope of TNF-α. 
     
     
         65 . The method of  claim 48 , wherein the immunogenic fragment is selected from the group consisting of Fab fragments, scFv, and F(ab)2 fragments. 
     
     
         66 . The method of  claim 44 , wherein the antibody that blocks TNF-α activity is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. 
     
     
         67 . The method of  claim 66 , wherein the pharmaceutical composition is a liquid solution, an emulsion, or a suspension. 
     
     
         68 . The method of  claim 66 , wherein the pharmaceutical composition comprises a carrier selected from gum Arabic, xanthan gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, polyvinylalcohol, ethyl oleate, a glycol, a polyethylene sorbitan fatty acid ester surfactant, and lecithin. 
     
     
         69 . The method of  claim 66 , wherein the pharmaceutical composition comprises lidocaine hydrochloride. 
     
     
         70 . The method of  claim 44 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2012093816A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.